Drug intelligence / Profile preview

CC-220 + itraconazole

Development stage: Unknown
Lead developer: Bristol Myers Squibb
Modality: Small Molecules
Administration: Oral, Intravenous (itraconazole)

Overview

This is a combination of **CC-220 (iberdomide)** and **itraconazole**. - **CC-220 (iberdomide)** is a novel immunomodulatory drug and cereblon modulator, developed for the treatment of relapsed/refractory multiple myeloma and systemic lupus erythematosus. It binds with high affinity to cereblon, a substrate receptor of the CRL4^CRBN^ E3 ubiquitin ligase, facilitating the ubiquitination and degradation of the transcription factors IKZF1 (Ikaros) and IKZF3 (Aiolos), which is believed to mediate its antitumor and immunomodulatory effects. - **Itraconazole** is a triazole antifungal agent used for the treatment and prophylaxis of various systemic and superficial fungal infections. It inhibits fungal 14α-demethylase (a CYP450 enzyme), disrupting ergosterol synthesis and compromising fungal cell membrane integrity.

Brand names: SporanoxTolsura
Other names: iberdomide

Targets

STAT3 (Signal Transducer and Activator of Transcription 3)PIK3R1 (Phosphoinositide-3-kinase regulatory subunit 1)6HB (SARS-CoV-2 spike protein HR1/HR2 six-helix bundle interface)CYP51A1 (Sterol 14α-demethylase)IKZF3 (Zinc finger protein Aiolos)SMO (Smoothened)IKZF1 (Ikaros family zinc finger protein 1)CRBN (Cereblon)

Beyond the preview

Go deeper on CC-220 + itraconazole.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CC-220 + itraconazole.

Explore the full profile